The Novel Role of GDI2: A Mini-Review.

Y Wu, G Y Chen

Abstract read

In one paragraph

Article in Annals of medicine and medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

GDI2 protein: research progress and its mechanisms in diseases.Frontiers in cell and developmental biology · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Y WuDepartment of Pediatrics, Children's Foundation Research Institute at Le Bonheur Children's Hospital, University of Tennessee Health Science Center, USA.

G Y ChenDepartment of Pediatrics, Children's Foundation Research Institute at Le Bonheur Children's Hospital, University of Tennessee Health Science Center, USA.

Funding

Targeting Siglec-9/E for therapy of sepsisR01AI137255 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI CHEN, GUOYUN · 2018 to 2022

$1.9M

The molecular mechanism of Siglec-E in bacterial clearanceR01AI179632 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Guoyun Chen · 2024 to 2026

$1.4M

NIAID NIH HHS R01 AI137255NIAID NIH HHS R01 AI179632

6 · The paper itself

Abstract

GDP Dissociation Inhibitor 2 (GDI2) plays a crucial role in maintaining cellular homeostasis by regulating Rab GTPases involved in vesicular transport. This review highlights the importance of GDI2 in various biological processes, particularly embryonic development, apoptosis regulation, cancer, and immune responses. GDI2's essential function in embryonic development is evidenced by the embryonic lethality observed in GDI2 knockout mice. In apoptosis, GDI2 is implicated in the caspase pathway, influencing cell survival and death. In cancer, dysregulation of GDI2 contributes to altered tumor cell-macrophage interactions, promoting inflammation and metastasis, with GDI2 acting as a metastasis suppressor in certain cancers. Furthermore, GDI2's role in immune responses, particularly during bacterial infections, and its potential therapeutic implications in conditions like Alzheimer's disease are explored. This review emphasizes the need for further research to elucidate the molecular mechanisms of GDI2 and its potential as a therapeutic target in developmental disorders, cancer, and immune-related diseases.

Identifiers

PMID39831280

PMCPMC11742367

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.